Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion
The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included
We haven't written up this one. Quartz has the full story — the link below goes straight to it.